The US Food and Drug Administration (FDA) is adding the risk of anaphylaxis to a new boxed warning of glatiramer acetate, a medicine for multiple sclerosis (MS). The agency issued the warning ...

In contrast, glatiramer acetate and dimethyl fumarate were initially used equally between genders, but eventually became more commonly prescribed to women (ORs 1.27 [95% CI 1.13–1.43], OR 1.17 ...

Teva's last remaining Copaxone (glatiramer acetate) patent expired in Europe in February 2015 and the Commission said last March it was investigating whether the company acted lawfully in trying ...

Along with the fine, the long-running investigation has concluded that Teva used a "web" of patents to illegally block lower-cost generic versions of Copaxone (glatiramer acetate), whose last ...

Shortly thereafter, glatiramer acetate (GA) was approved as well. These approvals subsequently triggered intense pharmaceutical research, leading to the numerous options available today that have ...

Effect of Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis in Subjects Presenting with a Clinically Isolated Syndrome; SC: Subcutaneous. Table 2.